Most Read Articles
01 Jan 2015
Ginkgo biloba has been shown to improve cognitive as well as neuropsychiatric symptoms (NPS) in patients with Alzheimer’s disease (AD) and mixed dementia. During a Schwabe-sponsored symposium last 20 October 2014 held at the University of Malaya in Malaysia, Professor Serge Gauthier of the McGill Centre for Studies in Aging in Quebec, Canada, and Dr Robert Hoerr of the Dr Willmar Schwabe GmbH & Co. KG in Germany, discussed studies that support the safety and efficacy of Ginkgo biloba extract (EGb 761®) in patients with AD and dementia.
26 Aug 2017
Elderly individuals with high levels of serum uric acid may be at an increased risk of dementia, particularly vascular or mixed dementia, a study suggests.
Elvira Manzano, 01 Feb 2014

There is no benefit to using ibuprofen over paracetamol in most patients with upper respiratory tract infections (URTIs). Steam inhalation therapy also does not offer any advantage, research has shown.

Dr. Joseph Delano Fule Robles, 01 Mar 2017

The tau and Aβ amyloid pathways have emerged as possible novel targets in treating Alzheimer’s disease (AD), according to studies discussed at the recently concluded Hong Kong Pharmacy Conference.

Poor balance control, lower nucleus accumbens volume in AD patients

14 Aug 2017
Brain tricks: The fact that déjà vu occurs so randomly and rapidly—and in individuals without a medical condition—makes it difficult to study, and why and how the phenomenon occurs is up to much speculation.

Patients with Alzheimer’s disease (AD) have poor balance control potentially as a result of loss of volume in the nucleus accumbens, a recent observational study has shown.

The study included 107 AD patients (mean age 70.2±8.3 years) and 37 healthy controls (64.4±6.1 years). Exclusion criteria were a Mini Mental State Examination (MMSE) score of <10, conditions that affect posture and other types of dementia.

Neuropsychological parameters were assessed using the MMSE and the Seoul Neuropsychological Screening Battery (SNSB). Computerized dynamic posturography was used to quantitatively evaluate postural control.

Compared with controls, AD patients had significantly higher frequency of falls (1.49±1.92 vs 4.67±1.84; p<0.001) and mean sway velocity (1.14±0.31 vs 1.33±0.43; p<0.05), and lower mean time to fall (4.55±2.36 vs 3.02±2.17; p<0.05) during the eyes open (EO) condition.

Composite scores in the sensory organization test (SOT) were also significantly lower in the AD patients than in controls (74.73±7.80 vs 78.30±4.62; p<0.05).

Participants with fall frequency >3 had significantly lower putamen (p<0.05) and nucleus accumbens (p<0.001) volume, and lower verbal memory, visual memory, visuospatial function and frontal-executive function scores (p<0.001 for all) than those with fall frequency <4.

On the other hand, patients in the lower 50 percent of SOT composite scores had significantly lower hippocampus (p<0.05), thalamus (p<0.05) and nucleus accumbens (p<0.001) volumes, and lower verbal memory (p<0.05) and frontal-executive function (p=0.000) scores than those in the upper 50 percent of SOT composite scores.

Editor's Recommendations
Most Read Articles
01 Jan 2015
Ginkgo biloba has been shown to improve cognitive as well as neuropsychiatric symptoms (NPS) in patients with Alzheimer’s disease (AD) and mixed dementia. During a Schwabe-sponsored symposium last 20 October 2014 held at the University of Malaya in Malaysia, Professor Serge Gauthier of the McGill Centre for Studies in Aging in Quebec, Canada, and Dr Robert Hoerr of the Dr Willmar Schwabe GmbH & Co. KG in Germany, discussed studies that support the safety and efficacy of Ginkgo biloba extract (EGb 761®) in patients with AD and dementia.
26 Aug 2017
Elderly individuals with high levels of serum uric acid may be at an increased risk of dementia, particularly vascular or mixed dementia, a study suggests.
Elvira Manzano, 01 Feb 2014

There is no benefit to using ibuprofen over paracetamol in most patients with upper respiratory tract infections (URTIs). Steam inhalation therapy also does not offer any advantage, research has shown.

Dr. Joseph Delano Fule Robles, 01 Mar 2017

The tau and Aβ amyloid pathways have emerged as possible novel targets in treating Alzheimer’s disease (AD), according to studies discussed at the recently concluded Hong Kong Pharmacy Conference.